TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25019114

Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite 15% toothpaste
Number of subjects: 105

Group type: COMPARATOR
Intervention: fluoride toothpaste
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 23052518

Group type: EXPERIMENTAL
Intervention: Kumar clamp
Number of subjects: 59

Group type: COMPARATOR
Intervention: Olsen clamp
Number of subjects: 59
Study: 20627268

Group type: EXPERIMENTAL
Intervention: computerized cognitive-behavioral therapy (cCBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 100

Group type: COMPARATOR
Intervention: in-person CBT
Number of subjects: 100
Study: 18361267

Group type: EXPERIMENTAL
Intervention: Lymph drainage performed four or five times per week for 30 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (Group B) received a type of massage for the same period and at the same frequency
Number of subjects: 25
Study: 16964830

Group type: EXPERIMENTAL
Intervention: Amdoxovir (300 mg orally, twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14576731

Group type: EXPERIMENTAL
Intervention: Pre-transplant minimal residual disease (MRD) level
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pre-transplant minimal residual disease (MRD) status
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sequential MRD monitoring post-ASCT
Number of subjects: 31
Study: 10990114

Group type: EXPERIMENTAL
Intervention: Heparin-bonded central venous lines (HB CVLs)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Non-heparin-bonded central venous lines (NHB CVLs)
Number of subjects: 209
Study: 9013400

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Haloperidol + Biperidene (HAL + BIP)
Number of subjects: 15
Study: 1550145

Group type: EXPERIMENTAL
Intervention: Oral erythromycin 333 mg every 8 hours from randomization to delivery
Number of subjects: 220

Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 220
Study: 3902238

Group type: EXPERIMENTAL
Intervention: mianserin (30 mg/day for the first week, then doubled for the next three weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: maprotiline (75 mg/day for the first week, then doubled for the next three weeks)
Number of subjects: 62
Study: 31246553

Group type: EXPERIMENTAL
Intervention: Text message notification
Number of subjects: 4947

Group type: EXPERIMENTAL
Intervention: Cell phone call notification
Number of subjects: 4947

Group type: EXPERIMENTAL
Intervention: Clinic visit notification
Number of subjects: 4947

Group type: EXPERIMENTAL
Intervention: Home visit notification
Number of subjects: 4947

Group type: COMPARATOR
Intervention: Home visit
Number of subjects: 4947

Group type: COMPARATOR
Intervention: Clinic visit
Number of subjects: 4947

Group type: EXPERIMENTAL
Intervention: Overall notification methods
Number of subjects: 4947
Study: 28625540

Group type: EXPERIMENTAL
Intervention: Sitting with breaks + high-energy diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Uninterrupted sitting + high-energy diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-energy diet
Number of subjects: 13
Study: 27165240

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 30 mg/m2 and paclitaxel 35 mg/m2 for 5‐6 weeks along with radiotherapy
Number of subjects: 25
Study: 24858423

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 22610335

Group type: EXPERIMENTAL
Intervention: Routine method (chisels)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: High speed turbine handpiece
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Piezosurgery device
Number of subjects: 300
Study: 20301828

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided deep peroneal nerve block
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional landmark technique deep peroneal nerve block
Number of subjects: 18
Study: 17583561

Group type: EXPERIMENTAL
Intervention: 18-gauge needle
Number of subjects: 42

Group type: COMPARATOR
Intervention: 21-gauge needle
Number of subjects: 42
Study: 15912390

Group type: EXPERIMENTAL
Intervention: 0.5% aqueous and 0.1% hydrogel formulations of timolol
Number of subjects: 25
Study: 12005083

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 95
Study: 9659094

Group type: EXPERIMENTAL
Intervention: Pulse oximeter measurements
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oscillometric device measurements
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intra-arterial measurements
Number of subjects: 46
Study: 7815679

Group type: EXPERIMENTAL
Intervention: Closed-system containers (CS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open systems decanted from cans (OS-Can)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open systems mixed from powder (OS-Powder)
Number of subjects: 100
Study: 2550244

Group type: EXPERIMENTAL
Intervention: CGS 16617 50 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Single ascending doses of CGS 16617 (20 to 100 mg)
Number of subjects: 17
Study: 31758661

Group type: EXPERIMENTAL
Intervention: Ubrogepant (MK‐1602)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 29970896

Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28859672

Group type: EXPERIMENTAL
Intervention: Laquinimod (0.9 mg to 2.7 mg, escalating doses)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 26338490

Group type: EXPERIMENTAL
Intervention: Coconut oil application (twice-daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 74
Study: 23631607

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg three times a day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg three times a day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nateglinide and Acarbose (both treatments)
Number of subjects: 103
Study: 20723033

Group type: EXPERIMENTAL
Intervention: Edoxaban 5 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: All Edoxaban doses
Number of subjects: 523
Study: 19092465

Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2%
Number of subjects: 210

Group type: COMPARATOR
Intervention: Fixed combination of timolol maleate 0.5%/dorzolamide 2%
Number of subjects: 210
Study: 17017227

Group type: EXPERIMENTAL
Intervention: 5% suspension concentrate beta‐cypermethrin (double dose 2S at 100 mg AI/m2)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 5% suspension concentrate beta‐cypermethrin (standard dose S at 50 mg AI/m2)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 25% cypermethrin (CF at 100 mg AI/m2)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 10% permethrin (DF at 170 mg AI/m2)
Number of subjects: 128
Study: 12818447

Group type: EXPERIMENTAL
Intervention: Tinidazole (T) 2g single dose + acidic vaginal gel (M) 2g every 3 days for 3 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vaginal clindamycin (CL) 2% for 7 days
Number of subjects: 64
Study: 10902934

Group type: EXPERIMENTAL
Intervention: Countermeasure (CM) group (n = 4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No-countermeasure (No-CM) group (n = 4)
Number of subjects: 8
Study: 9162305

Group type: EXPERIMENTAL
Intervention: Low-fat, high-dietary fiber, high-fruit and -vegetable eating pattern with dietary counseling
Number of subjects: 2079

Group type: COMPARATOR
Intervention: Usual dietary intake without counseling
Number of subjects: 2079
Study: 2000178

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) 100 UI/day intermuscular for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 6198368

Group type: EXPERIMENTAL
Intervention: Prophylactic oral and intravenous administration of kanamycin and metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exclusion of kanamycin
Number of subjects: 0
Study: 30699842

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (S‐adenosyl methionine; Folinic acid; Omega‐3 fatty acids; 5‐HTP; Zinc picolinate)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 28803178

Group type: EXPERIMENTAL
Intervention: SSIFL (short segment including fractured level)
Number of subjects: 74

Group type: COMPARATOR
Intervention: LS (long segment)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fusion (in both groups)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: SSIFL
Number of subjects: 74

Group type: COMPARATOR
Intervention: LS
Number of subjects: 74
Study: 26654862

Group type: EXPERIMENTAL
Intervention: Transfer within 1 hour after ICSI (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Transfer 3 days after ICSI (Group B, control group)
Number of subjects: 70
Study: 25086208

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 25
Study: 22694045

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus Nd:YAG laser (NDL) applications in nonsmoker patients (NST)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) in smoker patients (SP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus Nd:YAG laser (NDL) applications in smoker patients (ST)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) in nonsmoker patients (NSP)
Number of subjects: 52
Study: 19383806

Group type: EXPERIMENTAL
Intervention: 20 mg dual-release hydrocortisone tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg dual-release hydrocortisone tablet after a high-calorie, high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg dual-release hydrocortisone tablet
Number of subjects: 0
Study: 16616048

Group type: EXPERIMENTAL
Intervention: Stop-signal frequency manipulation (less frequent stop signals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stop-signal frequency manipulation (more frequent stop signals)
Number of subjects: 0
Study: 12882848

Group type: EXPERIMENTAL
Intervention: Population management with direct physician feedback
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study: 10994544

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 14 mg/m2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Idarubicin (IDR) 12 mg/m2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 30 mg/m2
Number of subjects: 17
Study: 8822745

Group type: EXPERIMENTAL
Intervention: Visual stimulation (stroboscopic light)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Visual deprivation (blindfolded)
Number of subjects: 6
Study: 1501561

Group type: EXPERIMENTAL
Intervention: Training at sea level at 70% maximal oxygen uptake (N = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Training at 2,500 m in a hypobaric chamber at 70% altitude VO2max (N = 14)
Number of subjects: 21
Study: 6563903

Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.1 mg/kg in 15 ml of normal saline
Number of subjects: 174

Group type: COMPARATOR
Intervention: Intramuscular morphine 0.1 mg/kg and normal saline 15 ml epidurally
Number of subjects: 174

Group type: COMPARATOR
Intervention: Normal saline 15 ml epidurally and normal saline 0.01 ml/kg intramuscularly
Number of subjects: 174
Study: 31930890

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy group (tongdu tiaoshen moxibustion + rehabilitation training)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation group (rehabilitation training only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation group
Number of subjects: 60
Study: 30123942

Group type: EXPERIMENTAL
Intervention: Risankizumab (0.01-5 mg/kg IV, 0.25-1 mg/kg SC, 18 mg SC, 90 mg SC, 180 mg SC for psoriasis; 200 or 600 mg IV every 4 weeks followed by 180 mg SC every 8 weeks for Crohn's disease)
Number of subjects: 272
Study: 30120772

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Control (placebo or ezetimibe)
Number of subjects: 3146
Study: 27487251

Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS) with wearable sensor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS)
Number of subjects: 0
Study: 24220044

Group type: EXPERIMENTAL
Intervention: Training in methods of preventing childhood obesity (5-day workshop on dietary and physical activity interventions, and motivational interviewing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 22435769

Group type: EXPERIMENTAL
Intervention: Videoconferencing therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Face to face therapy
Number of subjects: 6
Study: 19328269

Group type: COMPARATOR
Intervention: Frequent cyclers
Number of subjects: 121

Group type: COMPARATOR
Intervention: Moderate cyclers
Number of subjects: 121
Study: 17145205

Group type: EXPERIMENTAL
Intervention: Captopril 50mg tablet
Number of subjects: 25
Study: 16874150

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) training for 6 weeks (n=16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 24
Study: 12522748

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine with or without intranasal live‐attenuated, cold‐adapted influenza vaccine
Number of subjects: 2215
Study: 10669155

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 56
Study: 8844501

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous injections of inhalant allergens at the maximum intradermally tolerated dose (MITD)
Number of subjects: 36
Study: 1477693

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and alfentanil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Balanced anesthesia with isoflurane and alfentanil
Number of subjects: 43
Study: 6700813

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 26
Study: 31037721

Group type: EXPERIMENTAL
Intervention: Forced-air warming/water mattress (WarmTouch® and Norm‐O‐Temp®)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conductive fabric warming (HotDog® electric blanket and mattress)
Number of subjects: 35
Study: 29350831

Group type: EXPERIMENTAL
Intervention: Extended right lobe grafts (ERG)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Modified right lobe grafts (MRG)
Number of subjects: 86
Study: 27576515

Group type: EXPERIMENTAL
Intervention: Moderate exercise (150 min/week)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Extensive exercise (300 min/week)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 24421901

Group type: EXPERIMENTAL
Intervention: Tenofovir administered 2 doses/week for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir administered 4 doses/week for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir administered 7 doses/week for 6 weeks
Number of subjects: 24
Study: 23032981

Group type: EXPERIMENTAL
Intervention: Active TENS treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 144
Study: 20447871

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 325

Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 325
Study: 18569557

Group type: EXPERIMENTAL
Intervention: Partially detrained group (50% of previous training duration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Totally detrained group (no training)
Number of subjects: 16
Study: 16052841

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg twice/day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 12632885

Group type: EXPERIMENTAL
Intervention: V4R lead (Group V4R) instead of V1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard 12-lead ECG (Group V1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: V4R lead (Group V4R)
Number of subjects: 100
Study: 10365650

Group type: EXPERIMENTAL
Intervention: Clozapine + Sodium Valproate (n = 15)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clozapine (n = 22)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clozapine (200-400 mg/d) before and after Sodium Valproate (900-1200 mg/d) for 4 weeks (n = 6)
Number of subjects: 21
Study: 8523990

Group type: EXPERIMENTAL
Intervention: Patients with bilateral rapidly progressive SNHL
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Patients with Menière's disease
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (age-matched patients with no hearing complaints)
Number of subjects: 279
Study: 1911013

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.01 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no flumazenil)
Number of subjects: 20
Study: 6117682

Group type: EXPERIMENTAL
Intervention: Live influenza vaccine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Inactivated surface‐antigen influenza vaccine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 36
Study: 29884593

Group type: EXPERIMENTAL
Intervention: RIF-ATRA
Number of subjects: 109

Group type: COMPARATOR
Intervention: arsenic trioxide-ATRA
Number of subjects: 109
Study: 28829884

Group type: EXPERIMENTAL
Intervention: Oral Prednisolone (20 mg tablets, 2 tablets once daily for 5 days)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo (matched placebo, 2 tablets once daily for 5 days)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Oral Prednisolone
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 26609161

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 172
Study: 22878231

Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) with cathodal stimulation, 20 minutes per day, 5 days per week, for 4 weeks, combined with conventional physical therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham stimulation combined with conventional physical therapy
Number of subjects: 90
Study: 21401253

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning (EC) procedure that paired images of snack foods with images of potential adverse health consequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition featuring images of snack foods alone
Number of subjects: 0
Study: 18163509

Group type: EXPERIMENTAL
Intervention: Infliximab every 6 weeks (continuous treatment)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Infliximab upon symptom recurrence (on-demand treatment)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Infliximab alone (on-demand treatment)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Methotrexate (MTX) in combination with infliximab (on-demand treatment)
Number of subjects: 247
Study: 16385520

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (MTX)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 799
Study: 14501633

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen during the preoperative period
Number of subjects: 53

Group type: COMPARATOR
Intervention: No preoperative analgesia
Number of subjects: 53
Study: 11032921

Group type: EXPERIMENTAL
Intervention: BAP group (bleomycin, actinomycin-D, and cisplatin)
Number of subjects: 16

Group type: COMPARATOR
Intervention: BEP group (bleomycin, etoposide, and cisplatin)
Number of subjects: 16
Study: 8625627

Group type: EXPERIMENTAL
Intervention: 0.43 IU recombinant growth hormone/kg body weight/day for 12 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline for 12 days
Number of subjects: 20
Study: 1425873

Group type: EXPERIMENTAL
Intervention: Topically applied methylprednisolone aceponate (MPA) at concentrations of 0.01% to 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topically applied methylprednisolone aceponate (MPA) at the highest dose
Number of subjects: 20
Study: 6516045

Group type: EXPERIMENTAL
Intervention: One-day surgery
Number of subjects: 350

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 350
Study: 31530840

Group type: EXPERIMENTAL
Intervention: NaF_a (experimental acidic sodium fluoride; 12500 ppmF-, pH 4.75)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NaF_n (experimental neutral sodium fluoride; 12500 ppmF-, pH 7.0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GB_a (acidic gel base; 0 ppmF-, pH 4.75)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GB_n (neutral gel base; 0 ppmF-, pH 7.0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AmF-NaF_a (experimental acidic amine/sodium fluoride; 12500 ppmF-, pH 4.75)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EG_a (acidic amine/sodium fluoride; Elmex Geleé, CP-GABA GmbH; 12500 ppmF-, pH 4.75)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no gel, without/with pellicle)
Number of subjects: 30
Study: 29753732

Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid for 8 weeks
Number of subjects: 19
Study: 27716313

Group type: EXPERIMENTAL
Intervention: Training and supportive supervision by paid Community Health Workers (CHWs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Training alone
Number of subjects: 82